-+ 0.00%
-+ 0.00%
-+ 0.00%

SCIENTURE BROADENS COMMERCIAL ACCESS FOR REZENOPY™, HIGHEST-DOSE FDA-APPROVED NALOXONE NASAL SPRAY, THROUGH GPO AGREEMENTS REACHING OVER 5,000 U.S. INSTITUTIONS

Reuters·03/11/2026 12:05:00

Please log in to view news